Changes in drug plasma concentrations of an extensively bound and highly extracted drug, propofol, in response to altered plasma binding.
about
Optimizing sedation in patients with acute brain injuryPropofol: a review of its role in pediatric anesthesia and sedationKidneys contribute to the extrahepatic clearance of propofol in humans, but not lungs and brainPharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery.Gastrointestinal delivery of propofol from fospropofol: its bioavailability and activity in rodents and human volunteersDisposition and pharmacodynamics of propofol during isovolaemic haemorrhage followed by crystalloid resuscitation in humans.The impact of extracorporeal life support and hypothermia on drug disposition in critically ill infants and children.The road map to oral bioavailability: an industrial perspective.Effects of cardiopulmonary bypass on propofol pharmacokinetics and bispectral index during coronary surgery.Drug absorption, distribution, metabolism and excretion considerations in critically ill adults.Lipophilicity Influences Drug Binding to α1-Acid Glycoprotein F1/S Variants But Not to the A Variant.The pharmacokinetics of propofol in ICU patients undergoing long-term sedation.Performance of target-controlled infusion of propofol using two different pharmacokinetic models in open heart surgery - a randomised controlled study.Enhanced sedative efficacy and delayed recovery in propofol anesthesia in a rat model of hepatic cirrhosis.Evaluation and optimisation of current milrinone prescribing for the treatment and prevention of low cardiac output syndrome in paediatric patients after open heart surgery using a physiology-based pharmacokinetic drug-disease model.Effect of acute hypervolemic hemodilution of 6% hydroxyethyl starch 130/0.4 on the EC50 of propofol at two clinical endpoints in patients.The effect of Diprivan (propofol) on phosphorylcholine surfaces during cardiopulmonary bypass--an in vitro investigation.Concentrations of remifentanil, propofol, fentanyl, and midazolam during rewarming from therapeutic hypothermia.The relationship between bispectral index and targeted propofol concentration is biphasic in patients with major burns.Pharmacodynamics of propofol in critically ill patients.Propofol is cardioprotective in a clinically relevant model of normothermic blood cardioplegic arrest and cardiopulmonary bypass.Application of a pharmacokinetics-pharmacodynamics approach to the free propofol plasma levels during coronary artery bypass grafting surgery with hypothermic cardiopulmonary bypass.Significant decreases in blood propofol concentrations during adrenalectomy for phaeochromocytoma.Evaluation of the use of the fourth version FloTrac system in cardiac output measurement before and after cardiopulmonary bypass.Geographic differences in the target-controlled infusion estimated concentration of propofol: bispectral index response curves.Propofol induces growth cone collapse and neurite retractions in chick explant culture.The effect of positive end-expiratory pressure ventilation on propofol concentrations during general anesthesia in humans.Metabolic Profiles of Propofol and Fospropofol: Clinical and Forensic Interpretative Aspects.
P2860
Q26752789-DC235CDF-5C74-47ED-A18B-D7B2909206B1Q26796361-946F52BA-BC39-4895-BE66-1BF93B0F1CCFQ34559496-2E6F7292-1D41-47D4-8FFA-4383C3DCFB2AQ35164864-9B4E249A-BEFD-4E09-96E3-ABA80A57307FQ35663327-FEB909F9-EB05-49CC-B4A4-71BDA1722E27Q35827429-21C28598-597B-45AF-88CB-3FF94B5A9B57Q36452379-6D107A06-9A8B-47CB-95EA-34E03AF2C9F6Q36543116-14404569-321C-4926-9BA2-3CC4D5F70382Q37152571-B47A8936-D05F-47AE-931B-9D7D8E493724Q38107537-3E470F8F-8C4D-42E2-962F-D00FF904D8A0Q38711124-100DBFF6-D805-4805-9035-B47B728A4F50Q39457828-D53A067E-3311-45BC-91A4-4B0F492A3A76Q41067080-69C97BDA-B0FB-41B4-BBFA-31E70FF49412Q41641715-27A61B36-9ABC-45AA-9256-679BCC4EF283Q42608257-FF9D4CE1-0205-4219-92E1-35B77A01F8F9Q43068288-7059A4FD-C5C9-4F64-90C6-28AABDD4694EQ43235403-5C17A487-C564-4625-8584-D0B27B79BCDBQ44889311-DD0957F2-ABB0-42AC-912C-1EABDBDAA46DQ45241650-3EC9C1F5-AFBD-4F81-9BAC-D0392AEF3046Q46466264-64B65B80-A5B7-4A54-B384-A498A8A6441FQ46547417-AF69FCC1-B916-43EF-86E6-CCB7BA2F4678Q47100348-86535360-AFED-4B25-9CF4-AFBC45535021Q47291994-869683C3-A62C-4EEE-8B19-4EBF264CEFE8Q48177268-B9AACDA5-FE30-4DCE-8543-F696AFF6E221Q48293124-D3E3310F-EDD6-482A-90E7-8E74270B9960Q48647615-8F3FD00B-A24D-4043-BD2D-689536E34EDAQ48663790-67D5E801-0FF8-43BC-A580-641AC28F19A6Q55476359-29E94A8E-DB04-4B12-B904-108D4AE86D55
P2860
Changes in drug plasma concentrations of an extensively bound and highly extracted drug, propofol, in response to altered plasma binding.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Changes in drug plasma concent ...... nse to altered plasma binding.
@en
Changes in drug plasma concent ...... nse to altered plasma binding.
@nl
type
label
Changes in drug plasma concent ...... nse to altered plasma binding.
@en
Changes in drug plasma concent ...... nse to altered plasma binding.
@nl
prefLabel
Changes in drug plasma concent ...... nse to altered plasma binding.
@en
Changes in drug plasma concent ...... nse to altered plasma binding.
@nl
P2093
P1476
Changes in drug plasma concent ...... nse to altered plasma binding.
@en
P2093
Fumio Goto
Haruhiko Hiraoka
Koujirou Yamamoto
Nobuhiro Okano
Ryuya Horiuchi
Toshihiro Morita
P304
P356
10.1016/J.CLPT.2003.12.004
P407
P577
2004-04-01T00:00:00Z